Malignancy-related tumor-induced osteomalacia is a rare but important entity. We report the first case of oncogenic renal phosphate wasting in the setting of a pancreaticobiliary malignancy. Our patient presented with refractory hypophosphatemia. Workup revealed high fibroblast growth factor 23 levels as well as a new pancreaticobiliary mass. All other causes of hypophosphatemia were ruled out. With tumor-induced osteomalacia, an accurate diagnosis and location of the offending tumor is essential for appropriate management and treatment.
WilkinsGEGranleeseSHegeleRGet al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab1995; 80: 1628–1634.
2.
MakMPda Costa e SilvaVTMartinRMet al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer2012; 20: 2195–2197.
3.
TantisattamoENgRC.Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature. Hawaii Med J2011; 70(7): 139–143.
4.
BanksJPenneyMDAndersonEG.Tumour induced hypophosphataemia associated with small cell carcinoma of the bronchus. Thorax1987; 42(11): 909–910.
